Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based

bevacizumab
peritoneal cancer
carcinoma
recurrent disease
cancer antigen 125
  • 392 views
  • 10 Jun, 2021
  • 45 locations
Carboplatin and Paclitaxel With or Without Cediranib in Treating Women With Relapsed Ovarian Epithelial Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer

dividing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether combination

combination chemotherapy
peritoneal cancer
ovarian epithelial cancer
paclitaxel
carboplatin
  • 41 views
  • 07 Nov, 2020
  • 6 locations
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer

This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with

vegf
thyroid dysfunction
liver metastasis
absolute neutrophil count
bevacizumab
  • 1729 views
  • 21 Jun, 2021
  • 212 locations
Does Cediranib With Paclitaxel or Cediranib and Olaparib Treat Advanced Endometrial Cancer Better Than Paclitaxel?

cediranib. Cediranib is a tablet medication and works by blocking new blood vessel formation. Cediranib has been tested in women with endometrial cancer before but not alongside chemotherapy treatment

liver metastasis
recurrent endometrial cancer
carcinosarcoma
carcinoma
recurrent disease
  • 30 views
  • 23 Jan, 2021
  • 11 locations
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer

chemotherapy for advanced/recurrent disease. Patients will be randomised to either placebo Cediranib and Olaparib or active Cediranib and Olaparib and will remain on treatment until progression of disease

platinum-based chemotherapy
anticoagulants
aptt
carcinoma
cervical carcinoma
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be

solid tumors
erbb2
adenocarcinoma
thromboplastin
neuropathy
  • 0 views
  • 21 Jun, 2021
  • 11 locations
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian

  • 0 views
  • 20 Jun, 2021
  • 121 locations
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating patients with germline BRCA mutated breast cancer that has spread to other places in the body (advanced

liver metastasis
solid tumors
oophorectomy
hysterectomy
azd6738
  • 0 views
  • 26 Jan, 2021
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian Triple Negative Breast Lung Prostate and Colorectal Cancers

cancer cells. Cediranib is a drug that may stop the blood vessel growth of cancer cells. This study has two components. In the phase 1 component of the study, researchers want to investigate how well

bevacizumab
peritoneal cancer
erbb2
BRCA1
fallopian tube
  • 31 views
  • 19 Jun, 2021
  • 1 location
WIRE - Novel Treatments in Renal Cell Cancer

Evaluation of proof of mechanism with relation to ktrans and/or CD8 count when 3 different IMPs are given as monotherapy or as combination therapy. These would be administered in the "window of opportunity", prior to nephrectomy in surgically resectable renal cell cancer

nephrectomy
pazopanib
temsirolimus
tyrosine
neutrophil count
  • 0 views
  • 01 Jun, 2021
  • 1 location